Individuals featured on this website have been compensated by ViiV Healthcare. Patients featured are either on every-2-month or once-monthly CABENUVA.

Make the switch to CABENUVA. Data from SOLAR, the first head-to-head switch study comparing every-2-month CABENUVA to continuing daily oral BIKTARVY1:

Challenges taking daily oral therapy

Efficacy results vs BIKTARVY

Patient preference findings

Calendar icon Calendar icon

You can offer people with HIV two months between doses.

CABENUVA is the only complete long-acting regimen for the treatment of HIV.

You can offer people with HIV two months between doses.

CABENUVA is the only complete long-acting regimen for the treatment of HIV.

Identify patients for CABENUVA in your practice

“I was always concerned that somebody would find my pills and discover that I was HIV positive.”

Steve — Patient Ambassador

See Steve’s HIV treatment story

CABENUVA access and affordability

Get comprehensive support from benefit verification to reimbursement to acquisition to co-pay collection.

Start now

Questions to ask your patients about taking daily oral therapy

Question mark icon Question mark icon

“Do you hide your medication from those around you?”

“Is it difficult to remember to take your oral treatment every day?”

“Do you feel that your HIV medication is an uncomfortable daily reminder of your HIV status?”

Reference:

  1. Ramgopal MN, Castagna A, Cazanave C, et al. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. Lancet HIV. 2023;10(9):E566-E577. doi.org/10.1016/S2352-3018(23)00136-4

CBRWCNT230015